Nadroparin calcium

Names
Trade names| Fraxiparin(e), Fraxodi, others

IUPAC name

* (4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate

Clinical data
Routes of
use| Subcutaneous injection (except for haemodialysis)
External links
AHFS/Drugs.com| International Drug Names
Legal
Legal status|

* AU: S4 (Prescription only)
* CA: ℞-only

Pharmacokinetics
Bioavailability| 89% (SC dose)
Elimination half-life| 3.7 hours (SC dose)
Excretion| clearance 21.4mL/min (+/- 7)
Chemical and physical data
Molar mass| 4300 g/mol

Nadroparin (trade names Fraxiparin[e], Fraxodi, among others) is an anticoagulant used in general and orthopedic surgery to prevent thromboembolic disorders (deep vein thrombosis and pulmonary embolism), and as treatment for deep vein thrombosis. It is also used to prevent clotting during hemodialysis, and for treatment of unstable angina and non-Q wave myocardial infarction.[1] It is given by injection under the skin.

It is in the low molecular weight heparin (LMWH) class.

It is on the World Health Organization's List of Essential Medicines as an alternative to enoxaparin.[2]

## History[edit | edit source]

Nadroparin was developed by Sanofi-Synthélabo.

## References[edit | edit source]

1. ↑ "Fraxiparine PRODUCT MONOGRAPH (Canada)" (PDF). Aspripharma.com. Archived (PDF) from the original on 10 May 2017. Retrieved 2 April 2019.
2. ↑ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

## External links[edit | edit source]

Identifiers:|

* ATC code:

* B01AB06 (WHO)

* CAS Number: 9005-49-6 N
* DrugBank:

* DB08813 N

* ChemSpider:

* none

* UNII:

* 1K5KDI46KZ

* KEGG:

* D07510 N

|

* "NCI Drug Dictionary". National Cancer Institute. 2 February 2011. Archived from the original on 10 August 2019. Retrieved 2 April 2019.
* Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A (2006). "A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study". Pharmacology. 78 (3): 136–43. doi:10.1159/000096484. PMID 17057417. S2CID 95878036.

* v
* t
* e

Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)

Antiplatelet drugs|

| Glycoprotein IIb/IIIa inhibitors|

* Abciximab
* Eptifibatide
* Orbofiban
* Roxifiban
* Sibrafiban§
* Tirofiban

|

ADP receptor/P2Y12 inhibitors|

* Thienopyridines
* Clopidogrel
* Prasugrel
* Ticlopidine
* Nucleotide/nucleoside analogs
* Cangrelor
* Elinogrel
* Ticagrelor

Prostaglandin analogue (PGI2)|

* Beraprost
* Iloprost
* Prostacyclin
* Treprostinil

COX inhibitors|

* Acetylsalicylic acid/Aspirin#
* Aloxiprin
* Carbasalate calcium
* Indobufen
* Triflusal

Thromboxane inhibitors|

* Thromboxane synthase inhibitors
* Dipyridamole (\+ aspirin)
* Picotamide
* Terbogrel
* Receptor antagonists
* Terbogrel
* Terutroban§

Phosphodiesterase inhibitors|

* Cilostazol
* Dipyridamole
* Triflusal

Other|

* Cloricromen
* Ditazole
* Vorapaxar

Anticoagulants|

| Vitamin K antagonists
(inhibit II, VII, IX, X)|

* Coumarins: Acenocoumarol
* Coumatetralyl
* Dicoumarol
* Ethyl biscoumacetate
* Phenprocoumon
* Warfarin#
* 1,3-Indandiones: Clorindione
* Diphenadione
* Phenindione
* Other: Tioclomarol

|

Factor Xa inhibitors
(with some II inhibition)|

| Heparin group/
glycosaminoglycans/
(bind antithrombin)|

* Low-molecular-weight heparin
* Bemiparin
* Certoparin
* Dalteparin
* Enoxaparin
* Nadroparin
* Parnaparin
* Reviparin
* Tinzaparin
* Oligosaccharides
* Fondaparinux
* Idraparinux§
* Heparinoids
* Danaparoid
* Dermatan sulfate
* Sulodexide

|

Direct Xa inhibitors ("xabans")|

* Apixaban
* Betrixaban
* Darexaban§
* Edoxaban
* Otamixaban§
* Rivaroxaban

Direct thrombin (IIa) inhibitors|

* Bivalent: Hirudin
* Bivalirudin
* Desirudin
* Lepirudin‡
* Univalent: Argatroban
* Dabigatran
* Efegatran
* Inogatran§
* Melagatran‡
* Ximelagatran‡

Other|

* Antithrombin III
* Defibrotide
* Protein C
* Drotrecogin alfa‡
* Ramatroban
* REG1

Thrombolytic drugs/
fibrinolytics|

* Plasminogen activators: r-tPA
* Alteplase#
* Reteplase
* Tenecteplase
* Desmoteplase†
* UPA
* Saruplase
* Urokinase
* Anistreplase
* Monteplase
* Streptokinase#
* Other serine endopeptidases: Ancrod‡
* Brinase
* Fibrinolysin

Non-medicinal|

* Citrate
* EDTA
* Oxalate

* #WHO-EM
* ‡Withdrawn from market
* Clinical trials:
* †Phase III
* §Never to phase III

This drug article relating to the blood and blood forming organs is a stub. You can help MDWiki by expanding it.

|

* v
* t
* e

*[AU]: Australia
*[CA]: Canada
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template